Windtree pre-announces $4.2M cash at Q1 end; net cash used $2.9M in Q1

WINDTREE THERAPEUTICS INC /DE/

Cash and cash equivalents estimated at ~$4.2 million as of March 31, 2023.
Net cash used before financing activities for Q1 2023 was $2.9 million.
These are preliminary estimates; final Q1 results may differ materially.
Company's cash burn rate raises potential going-concern risk for micro-cap biotech.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

WINDTREE THERAPEUTICS INC /DE/ reported preliminary financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: preliminary results

Exact text from the filing

Windtree Therapeutics, Inc. (the “Company”) is disclosing certain preliminary financial results for the first quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-23-009713

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.